Drugs / Gonapeptyl
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03809429 | Apr 2019 → Feb 2022 | female infertility | Ferring Pharmaceuticals | Completed | Met primary |
| Comparator or background therapy4 trials | ||||||
| Phase 3 | NCT03767218 Background | Nov 2018 → May 2022 | female infertility | University Hospital Brussels | Completed | No outcome recorded |
| Phase 4 | NCT06175832 Background | Jan 2025 → Dec 2027 expected | — | University Hospital, Ghent | Recruiting | No outcome recorded |
| — | NCT05521828 Background | Apr 2023 → Sep 2024 | — | CRG UZ Brussel | Unknown | No outcome recorded |
| — | NCT03142035 Comparator | Oct 2017 → Feb 2023 | endometriosis | American University of Beirut Medical Center | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gonapeptyl | “Oocyte maturation trigger with GnRH agonist (0.2mg Gonapeptyl) in both groups.” NCT03767218 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of GnRH agonist (0.2 mg Gonapeptyl)” NCT05521828 ↗ |